Oct 2026· Frontiers in Immunology· Vol 17· 0 citations· 133 references
Medicine
TL;DR
This review synthesizes current understanding of disease mechanisms, molecular profiling evidence, biomarker candidates, and mechanism-directed therapies corresponding to each tissue injury program and delineates the design requirements for prospective biomarker-stratified trials essential to validating molecularly guided treatment selection.
Abstract
Lupus nephritis (LN) develops in 40–60% of patients with systemic lupus erythematosus (SLE) and remains the leading cause of renal morbidity and progression to end-stage renal disease (ESRD). While the upstream immunological events initiating LN—including loss of self-tolerance, pathogenic autoantibody production, glomerular immune complex deposition, and type I interferon (IFN) activation—are broadly shared, accumulating evidence demonstrates that these convergent triggers give rise to molecularly heterogeneous tissue injury programs at the renal level. This fundamental divergence provides a mechanistic explanation for the inconsistent therapeutic responses observed with standardized immunosuppressive protocols. Advances in single-cell transcriptomics, spatial gene expression mapping, CITE-seq, and cross-platform multi-omic integration have deconvolved this heterogeneity into at least five recognizable tissue-level injury programs: (i) an IFN-γ-polarized macrophage–tubular epithelial cell co-activation circuit, (ii) a Tfh–B cell ectopic germinal center pathway, (iii) a neutrophil extracellular trap (NET)-driven inflammatory cascade, (iv) a podocyte-autonomous injury program, and (v) a TREM2+ macrophage-orchestrated fibrotic program. Concurrently, multiplexed urinary biomarker platforms are under development as non-invasive surrogates for tissue-level pathogenic activity. This review synthesizes current understanding of disease mechanisms, molecular profiling evidence, biomarker candidates, and mechanism-directed therapies corresponding to each tissue injury program. We map existing and investigational agents—including anifrolumab, obinutuzumab, voclosporin, CAR-T cell therapy, and complement inhibitors—to their mechanistic targets and delineate the design requirements for prospective biomarker-stratified trials essential to validating molecularly guided treatment selection.
The spectrum of T-cell abnormalities in SLE is synthesized and it is proposed that these phenotypes arise from four interacting layers of dysregulation: extracellular cues including cytokine and non-cytokine mediators and altered antigen presentation, T-cell receptor (TCR) and co-stimulatory signaling, immunometabolic...
In many immune-mediated kidney diseases, tissue injury is driven by dysregulated B-cell immunity, with autoantibodies and complement acting as key effectors at the glomerulus. Corticosteroids and conventional immunosuppressants control these diseases only in part, and they do so at the price of cumulative toxicity and...
L. Visconti, L. Soraci, Lorenzo Lo Cicero et al.· Future Pharmacology· 0 citations
Systemic lupus erythematosus (SLE) is a clinically defined syndrome arising from heterogeneous and dynamically interacting molecular programs. Recent transcriptomic, single-cell, spatial, and functional studies have identified recurrent molecular states; however, published three-, five-, six-, and eight-group taxonomie...
Y. Terajima, Yoshinori Matsumoto, S. Nawachi et al.· Frontiers in Immunology· 0 citations
Poor response of lupus nephritis (LN) to conventional therapies frequently results in persistent renal inflammation and progression of chronic renal insufficiency. The complex pathogenesis of LN, characterized by microregional immune heterogeneity and interregional crosstalk, greatly hinders identification of the core...
Lin Liu, Ao Li, Qiong Guo et al.· Scientific Reports· 0 citations
Kawasaki disease (KD) is an immune-mediated pediatric vasculitis characterized by dynamic interactions among genetic susceptibility, innate and adaptive immune activation, endothelial dysfunction, and vascular remodeling. Although intravenous immunoglobulin (IVIG) therapy substantially reduces coronary complications, 1...
Yun-Yong Han, Jia-Ying Liu, Cheng-Xu Song et al.· Frontiers in Pediatrics· 0 citations
Persistent autoantibody production after conventional immunosuppression or B-cell depletion has focused attention on antibody-secreting cells that survive without ongoing proliferation. Long-lived plasma cells (LLPCs) are indispensable for durable protective immunity, but autoreactive members of this compartment may al...
Hong-Hao Guo, Wang Xiang, Liu-Ting Zeng et al.· Autoimmunity Reviews· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.